Rankings
Pricing
Log In
Free Trial
US-listed companies
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc.
TARS
Market cap
$1.1B
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
iso4217:USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2023
Net loss
-136
Depreciation
1
Stock-based compensation
20
Amortization of intangible assets
0
Accretion of term loan-related costs
0
Stock-based compensation
20
Non-cash lease expense
1
Accretion of term loan-related costs
0
Non-cash lease expense
1
Net amortization/accretion on marketable securities
3
Unrealized (gain) loss on equity investment
0
Change in fair value of equity warrants issued by licensee
0
Other receivables
-2
Accounts receivable, net
17
Prepaid expenses
3
Inventory
3
Other non-current assets
1
Other receivables
-2
Accounts payable and other accrued liabilities
13
Prepaid expenses
3
Accrued payroll and benefits
8
Other non-current assets
1
Other long-term liabilities
0
Accounts payable and other accrued liabilities
13
Accrued payroll and benefits
8
Other long-term liabilities
0
Other receivables
-2
Accounts receivable, net
17
Prepaid expenses
3
Inventory
3
Other non-current assets
1
Other receivables
-2
Accounts payable and other accrued liabilities
13
Prepaid expenses
3
Accrued payroll and benefits
8
Other non-current assets
1
Other long-term liabilities
0
Accounts payable and other accrued liabilities
13
Accrued payroll and benefits
8
Other long-term liabilities
0
Net cash used in by operating activities
-117
Net loss
-136
Depreciation
1
Stock-based compensation
20
Amortization of intangible assets
0
Accretion of term loan-related costs
0
Stock-based compensation
20
Non-cash lease expense
1
Accretion of term loan-related costs
0
Non-cash lease expense
1
Net amortization/accretion on marketable securities
3
Unrealized (gain) loss on equity investment
0
Change in fair value of equity warrants issued by licensee
0
Other receivables
-2
Accounts receivable, net
17
Prepaid expenses
3
Inventory
3
Other non-current assets
1
Other receivables
-2
Accounts payable and other accrued liabilities
13
Prepaid expenses
3
Accrued payroll and benefits
8
Other non-current assets
1
Other long-term liabilities
0
Accounts payable and other accrued liabilities
13
Accrued payroll and benefits
8
Other long-term liabilities
0
Other receivables
-2
Accounts receivable, net
17
Prepaid expenses
3
Inventory
3
Other non-current assets
1
Other receivables
-2
Accounts payable and other accrued liabilities
13
Prepaid expenses
3
Accrued payroll and benefits
8
Other non-current assets
1
Other long-term liabilities
0
Accounts payable and other accrued liabilities
13
Accrued payroll and benefits
8
Other long-term liabilities
0
Net cash used in by operating activities
-117
Proceeds from sales of marketable securities
175
Purchases of marketable securities
29
Purchases of property and equipment
2
Intangible asset additions
4
Net cash provided by (used in) investing activities
141
Purchases of property and equipment
2
Net cash provided by (used in) investing activities
141
Follow-On Public Offering
99
2023 ATM Prospectus
19
Proceeds from term loan
10
Proceeds from sale of common stock under employee stock purchase plan
1
Proceeds from Stock Options Exercised
1
Net cash provided by financing activities
130
Net increase (decrease) in cash and cash equivalents
153
Interest expense paid in cash
3
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
2
Capital Expenditures Incurred but Not yet Paid
0
Interest expense paid in cash
3
Capital Expenditures Incurred but Not yet Paid
0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
2
Proceeds from sales of marketable securities
175
Purchases of marketable securities
29
Purchases of property and equipment
2
Intangible asset additions
4
Net cash provided by (used in) investing activities
141
Purchases of property and equipment
2
Net cash provided by (used in) investing activities
141
Follow-On Public Offering
99
2023 ATM Prospectus
19
Proceeds from term loan
10
Proceeds from sale of common stock under employee stock purchase plan
1
Proceeds from Stock Options Exercised
1
Net cash provided by financing activities
130
Net increase (decrease) in cash and cash equivalents
153
Interest expense paid in cash
3
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
2
Capital Expenditures Incurred but Not yet Paid
0
Interest expense paid in cash
3
Capital Expenditures Incurred but Not yet Paid
0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
2